While pharmacological inhibitors of PI3K and AKT have long been pursued as therapeutics in breast cancer, inhibitors have historically performed poorly in clinical trials due to off target effects/toxicity, such as autoimmune disorders, hypertension, dysregulation of blood glucose levels, and hepatotoxicity, among others[82,83]. The gene discussed is PIK3CA; the disease is breast cancer.